Trailblazing Alzheimer’s Drugs Move Into Late-Stage Development

Medivation's Dimebon, Elan/Wyeth's bapineuzumab and AstraZeneca/Targacept's AZD3480 are among several novel drugs targeting new mechanisms of action that are now moving into later stages of development for Alzheimer's disease